| A Mesoporous Gold Sensor Unveils Phospho PD-L1 in Extracellular Vesicles as a Proxy for PD-L1 Expression in Lung Cancer Tissue KB Shanmugasundaram, E Ahmed, X Miao, A Kulasinghe, JA Fletcher, ... ACS sensors, 2024 | | 2024 |
| Safety, tolerability, and dosimetry of TLX591 with best standard of care in patients with PSMA-expressing metastatic castration resistant prostate cancer (ProstACT SELECT … N Lenzo, K O'Byrne, S Ngai, D Meyrick, N Patel, C Hayward Journal of Nuclear Medicine 65 (supplement 2), 241503-241503, 2024 | | 2024 |
| Sequence- and Structure-Dependent Cytotoxicity of Phosphorothioate and 2′-O-Methyl Modified Single-Stranded Oligonucleotides LV Croft, M Fisher, TK Barbhuiya, S El-Kamand, S Beard, A Rajapakse, ... nucleic acid therapeutics 34 (3), 143-155, 2024 | | 2024 |
| The TSANZ and Lung Foundation Australia 2023 landscape survey of lung cancer care across Australia and Aotearoa New Zealand J Nash, T Leong, P Dawkins, E Stone, H Marshall, F Brims, ... Respirology 29 (5), 405-412, 2024 | | 2024 |
| Metabolomics at the tumor microenvironment interface: Decoding cellular conversations N Berrell, H Sadeghirad, T Blick, C Bidgood, GR Leggatt, K O'Byrne, ... Medicinal Research Reviews 44 (3), 1121-1146, 2024 | 1 | 2024 |
| Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells ET Shah, C Molloy, M Gough, T Kryza, SG Samuel, A Tucker, M Bhatia, ... British Journal of Cancer 130 (7), 1196-1205, 2024 | | 2024 |
| In situ characterization of the tumor microenvironment H Sadeghirad, VY Naei, K O’Byrne, ME Warkiani, A Kulasinghe Current Opinion in Biotechnology 86, 103083, 2024 | | 2024 |
| Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial PW Szlosarek, BC Creelan, T Sarkodie, L Nolan, P Taylor, O Olevsky, ... JAMA oncology 10 (4), 475-483, 2024 | 2 | 2024 |
| Spatially resolved cell profiling unveils tumor metabolic states associated with immunotherapy response in NSCLC J Monkman, R Czertok, S Bookstein, B Arbiv, Y Shachaf, R Elran, K Bloom, ... Cancer Research 84 (6_Supplement), 1158-1158, 2024 | | 2024 |
| Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy … H Sadeghirad, CW Tan, N Liu, J Monkman, C Cooper, K O’Byrne, M Davis, ... Cancer Research 84 (6_Supplement), 1154-1154, 2024 | | 2024 |
| Spatial insights into immunotherapy response in non-small cell lung cancer (NSCLC) by multiplexed tissue imaging J Monkman, A Moradi, J Yunis, G Ivison, A Mayer, R Ladwa, K O’Byrne, ... Journal of Translational Medicine 22 (1), 239, 2024 | | 2024 |
| A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE L Tan, C Brown, A Mersiades, CK Lee, T John, S Kao, G Newnham, ... Nature Communications 15 (1), 1823, 2024 | 1 | 2024 |
| Poor patient outcome correlates with active engulfment of cytokeratin positive CTCs within cancer-associated monocyte population in lung cancer AP Wiegmans, E Ivanova, VY Naei, J Monkman, J Fletcher, W Mullally, ... Clinical & Experimental Metastasis, 1-10, 2024 | | 2024 |
| Nucleic acid oligomers and uses therefor D Richard, K O'byrne, L Croft, S Beard US Patent 11,911,410, 2024 | | 2024 |
| Targeting the hSSB1-INTS3 Interface: A Computational Screening Driven Approach to Identify Potential Modulators TK Barbhuiya, S Beard, ET Shah, S Mason, E Bolderson, K O’Byrne, ... ACS omega 9 (7), 8362-8373, 2024 | | 2024 |
| Safety, tolerability, and dosimetry of 177Lu-TLX591 with best standard of care in patients with PSMA-expressing metastatic castration-resistant prostate cancer … N Lenzo, K O'Byrne, S Ngai, D Meyrick, N Patel, C Hayward Journal of Clinical Oncology 42 (4_suppl), TPS253-TPS253, 2024 | | 2024 |
| Lorlatinib After Alectinib-Induced Pneumonitis: A Case Report JA Fletcher, WJ Mullally, R Ladwa, KJ O’Byrne JTO Clinical and Research Reports 5 (2), 100591, 2024 | | 2024 |
| Glycan Profiling in Small Extracellular Vesicles with a SERS Microfluidic Biosensor Identifies Early Malignant Development in Lung Cancer Q Zhou, X Niu, Z Zhang, K O'Byrne, A Kulasinghe, D Fielding, A Möller, ... Advanced Science, 2401818, 2024 | | 2024 |
| Characterisation of circulating tumor‐associated and immune cells in patients with advanced‐stage non‐small cell lung cancer V Yaghoubi Naei, E Ivanova, W Mullally, CG O'Leary, R Ladwa, K O'Byrne, ... Clinical & Translational Immunology 13 (6), e1516, 2024 | | 2024 |
| The expression and role of the Lem-D proteins Ankle2, Emerin, Lemd2, and TMPO in triple-negative breast cancer cell growth M Rose, JT Burgess, CM Cheong, MN Adams, P Shahrouzi, KJ O’Byrne, ... Frontiers in Oncology 14, 2024 | | 2024 |
